Unique SLC39A13: Potential Drug Target & Biomarker (G91252)

Target Name: SLC39A13

NCBI ID: G91252

SLC39A13

Unique SLC39A13: Potential Drug Target & Biomarker

SLC39A13 (Zrt- and Irt-like protein 13) is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and kidney. It is a member of the SLC (Sodium Chloride) family, which is known for its role in the transport of electrolytes into and out of cells. SLC39A13 has unique features that make it different from other proteins in the SLC family, including its ability to interact with certain molecules called ligands and its role in various physiological processes in the body.

One of the unique features of SLC39A13 is its ability to interact with certain molecules called ligands. A ligand is a small molecule that can interact with a protein, such as amino acids, hormones or other molecules in the protein. These ligands can influence the function of a protein, including its structure, activity, and interactions. Ligands for SLC39A13 include many different molecules, such as insulin, growth factors, cytokines, and neurotransmitters. The interaction of these ligands with SLC39A13 can lead to structural changes in SLC39A13, thereby affecting its function.

SLC39A13 is involved in various physiological processes in the body, including the regulation of blood pressure, the balance of fluids and electrolytes in the body, and the transport of nutrients into cells. It is also involved in the regulation of gene expression, which is the process by which the instructions in a cell's DNA are used to produce the proteins that are needed for various functions. SLC39A13 has been shown to play a role in the regulation of gene expression in various tissues of the body, including the brain and the liver.

SLC39A13 is also of interest because it has been shown to be a potential drug target (or biomarker) in various diseases. For example, SLC39A13 has been shown to be involved in the regulation of blood pressure, which is a risk factor for heart disease and stroke. It is also involved in the regulation of inflammation, which is a contributing factor to various diseases including autoimmune disorders and chronic infections. SLC39A13 may also be involved in the regulation of cell division and growth, which is a factor in the development and progression of cancer.

In conclusion, SLC39A13 is a unique protein that is expressed in various tissues of the body and is involved in various physiological processes in the body. Its ability to interact with certain molecules called ligands and its role in various physiological processes, including the regulation of blood pressure, the balance of fluids and electrolytes in the body, and the transport of nutrients into cells, make it an interesting protein for research and potential drug development. Further research is needed to fully understand the functions of SLC39A13 and its potential as a drug target (or biomarker) in various diseases.

Protein Name: Solute Carrier Family 39 Member 13

Functions: Functions as a zinc transporter transporting Zn(2+) from the Golgi apparatus to the cytosol and thus influences the zinc level at least in areas of the cytosol (PubMed:21917916, PubMed:23213233). May regulate beige adipocyte differentiation (By similarity)

The "SLC39A13 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC39A13 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets